Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 34

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 34
---
 ● | enforce and defend intellectual                                    
 property rights and claims with respect to our product candidates. |

Many of the factors listed
above are beyond our control and could cause us to experience significant delays or prevent us from obtaining regulatory approvals or
commercialize our product candidates. Even if we are able to commercialize our product candidates, we may not achieve profitability soon
after generating product sales, if ever. If we are unable to generate sufficient revenue through the sale of our product candidates or
any future product candidates, we may be unable to continue operations without continued funding.

<div align='center'>13</div>

Our engineered CER-T cells represent a novel approach to cancer treatment that creates significant challenges for us.

We are developing autologous
T-cell product candidates that are engineered from healthy donor T-cells to express chimeric engulfment receptors (“CERs”)
and are intended for use in patients with certain cancers. Advancing these novel product candidates creates significant challenges for
us, including:

| ● | manufacturing our product                                                                                                                  
 candidates to our or regulatory specifications and in a timely manner to support our clinical trials, and, if approved, commercialization; |

| ● | sourcing clinical and,                                                                             
 if approved, commercial supplies for the raw materials used to manufacture our product candidates; |

| ● | understanding and addressing                                                                                                
 variability in the quality of a donor’s T cells, which could ultimately affect our ability to produce product in a reliable 
 and consistent manner and treat certain patients;                                                                           |

| ● | educating medical personnel                                                                                                             
 regarding the potential side effect profile of our product candidates, if approved, such as the potential adverse side effects related  
 to CRS, neurotoxicity, prolonged cytopenia, coagulation abnormalities, thrombosis, hypotension, aplastic anemia and neutropenic sepsis; |

| ● | using medicines to preempt                                                                                                             
 or manage adverse side effects of our product candidates and such medicines may be difficult to source or costly or may not adequately 
 control the side effects or may have other safety risks or a detrimental impact on the efficacy of the treatment;                      |

| ● | conditioning patients with                                                                                                           
 cyclophosphamide, fludarabine, or bendamustine in advance of administering our product candidates, which may be difficult to source, 
 costly or increase the risk of infections and other adverse side effects;                                                            |

| ● | obtaining regulatory approval,                                                                                           
 as the FDA and other regulatory authorities have limited experience with development of